{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:47:52Z","timestamp":1785300472367,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Low urine pH, which may be mediated by metabolic syndrome (MetS), is common in gout. Tart cherries are shown to improve MetS symptoms and possess anti-inflammatory properties. However, the efficacy of tart cherry supplements on urine pH has yet to be studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aimed to investigate the efficacy and safety of tart cherry supplementary citrate (TaCCi) mixture on urine pH, serum urate (sUA), C-reactive protein (CRP), and gout flares in gout patients initiating urate-lowering therapy (ULT), in comparison to citrate mixture and sodium bicarbonate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective, randomized (1:1:1), open-label, parallel-controlled trial was conducted among 282 men with gout and fasting urine pH\u2009\u2264\u20096, who were initiating ULT with febuxostat (initially 20\u00a0mg daily, escalating to 40\u00a0mg daily if serum urate\u2009\u2265\u2009360\u00a0\u03bcmol\/L). Participants were randomized to groups taking either sodium bicarbonate, citrate mixture, or TaCCi mixture. All participants were followed every 4\u00a0weeks until week 12. Urine pH and sUA were co-primary outcomes, with various biochemical and clinical secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Urine pH increased to a similar extent in all three groups. SUA levels declined in all three groups as well, with no significant differences observed between the groups. At week 12, the TaCCi mixture group exhibited a greater reduction in the urine albumin\/creatinine ratio (UACR) compared to the other two groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Participants taking TaCCi mixture or citrate mixture experienced fewer gout flares than those in the sodium bicarbonate group over the study period (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Additionally, the TaCCi mixture group had a lower CRP level at week 12 relative to the other two groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Adverse events were similar across all three groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The TaCCi mixture had similar efficacy and safety on urine alkalization and sUA-lowering as the citrate mixture and sodium bicarbonate in patients with gout. However, the TaCCi mixture resulted in greater improvements in UACR and CRP, which suggests that tart cherry supplements may provide additional benefits for renal protection and reduce inflammation in gout, particularly when starting ULT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This project was registered in ChiCTR (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">www.chictr.org.cn<\/jats:ext-link>), with the registration number: ChiCTR2100050749.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03152-1","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T08:02:52Z","timestamp":1694073772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study"],"prefix":"10.1186","volume":"25","author":[{"given":"Can","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-5323","authenticated-orcid":false,"given":"Mingshu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-3731","authenticated-orcid":false,"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"issue":"1","key":"3152_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, Perissin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74(1):142\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3152_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/key096","volume":"57","author":"M Bevis","year":"2018","unstructured":"Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford). 2018;57(8):1358\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3152_CR3","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/rheumatology\/keq274","volume":"49","author":"HH Dao","year":"2010","unstructured":"Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology (Oxford). 2010;49(12):2400\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3152_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2215\/CJN.08331109","volume":"5","author":"NM Maalouf","year":"2010","unstructured":"Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"3152_CR5","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1681\/ASN.2006030262","volume":"17","author":"M Daudon","year":"2006","unstructured":"Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17(7):2026\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3152_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-022-02725-w","volume":"24","author":"Y He","year":"2022","unstructured":"He Y, Xue X, Terkeltaub R, Dalbeth N, Merriman TR, Mount DB, et al. Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study. Arthritis Res Ther. 2022;24(1):32.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"3152_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2215\/CJN.00670207","volume":"2","author":"NM Maalouf","year":"2007","unstructured":"Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2(5):883\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3152_CR8","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/j.1523-1755.2004.00522.x","volume":"65","author":"NM Maalouf","year":"2004","unstructured":"Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422\u20135.","journal-title":"Kidney Int"},{"issue":"13\u201314","key":"3152_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00508-022-02054-7","volume":"134","author":"J Sautner","year":"2022","unstructured":"Sautner J, Eichbauer-Sturm G, Gruber J, Lunzer R, Puchner RJ. 2022 update of the Austrian Society of Rheumatology and Rehabilitation nutrition and lifestyle recommendations for patients with gout and hyperuricemia. Wien Klin Wochenschr. 2022;134(13\u201314):546\u201354.","journal-title":"Wien Klin Wochenschr"},{"key":"3152_CR10","doi-asserted-by":"crossref","unstructured":"Golovinskaia O, Wang CK. Review of functional and pharmacological activities of berries. Molecules. 2021;26(13):3904.","DOI":"10.3390\/molecules26133904"},{"issue":"4","key":"3152_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11130-015-0509-2","volume":"70","author":"N Papp","year":"2015","unstructured":"Papp N, Blazovics A, Febel H, Salido S, Altarejos J, Feher E, et al. Antihyperlipidemic effects of sour cherries characterized by different in vitro antioxidant power and polyphenolic composition. Plant Foods Hum Nutr. 2015;70(4):408\u201313.","journal-title":"Plant Foods Hum Nutr"},{"key":"3152_CR12","doi-asserted-by":"crossref","unstructured":"Keane KM, George TW, Constantinou CL, Brown MA, Clifford T, Howatson G. Effects of Montmorency tart cherry (Prunus Cerasus L.) consumption on vascular function in men with early hypertension. Am J Clin Nutr. 2016;103(6):1531\u20139.","DOI":"10.3945\/ajcn.115.123869"},{"issue":"3","key":"3152_CR13","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00394-020-02355-5","volume":"60","author":"T Desai","year":"2021","unstructured":"Desai T, Roberts M, Bottoms L. Effects of short-term continuous Montmorency tart cherry juice supplementation in participants with metabolic syndrome. Eur J Nutr. 2021;60(3):1587\u2013603.","journal-title":"Eur J Nutr"},{"issue":"6","key":"3152_CR14","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/jn\/133.6.1826","volume":"133","author":"RA Jacob","year":"2003","unstructured":"Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003;133(6):1826\u20139.","journal-title":"J Nutr"},{"key":"3152_CR15","doi-asserted-by":"crossref","unstructured":"Martin KR, Coles KM. Consumption of 100% tart cherry juice reduces serum urate in overweight and obese adults. Curr Dev Nutr. 2019;3(5):nzz011.","DOI":"10.1093\/cdn\/nzz011"},{"issue":"9","key":"3152_CR16","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1093\/rheumatology\/kez606","volume":"59","author":"LK Stamp","year":"2020","unstructured":"Stamp LK, Chapman P, Frampton C, Duffull SB, Drake J, Zhang Y, et al. Lack of effect of tart cherry concentrate dose on serum urate in people with gout. Rheumatology (Oxford). 2020;59(9):2374\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3152_CR17","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/art.34677","volume":"64","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64(12):4004\u201311.","journal-title":"Arthritis Rheum"},{"key":"3152_CR18","doi-asserted-by":"crossref","unstructured":"Yan F, Xue X, Lu J, Dalbeth N, Qi H, Yu Q, et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis Rheumatol. 2022;74(12):2015\u201323.","DOI":"10.1002\/art.42266"},{"issue":"7","key":"3152_CR19","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1246.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3152_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772\u201387.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"3152_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3152_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3152_CR23","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa668","volume":"60","author":"X Xue","year":"2021","unstructured":"Xue X, Liu Z, Li X, Lu J, Wang C, Wang X, et al. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. Rheumatology (Oxford). 2021;60(6):2661\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3152_CR24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3152_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11926-012-0307-x","volume":"15","author":"JA Singh","year":"2013","unstructured":"Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15(2):307.","journal-title":"Curr Rheumatol Rep"},{"key":"3152_CR26","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gonzalez JG, Violante-Cumpa JR, Zambrano-Lucio M, Burciaga-Jimenez E, Castillo-Morales PL, Garcia-Campa M, et al. HOMA-IR as a predictor of health outcomes in patients with metabolic risk factors: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2022;29(6):547\u201364.","DOI":"10.1007\/s40292-022-00542-5"},{"issue":"5","key":"3152_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508\u201317.","journal-title":"Arthritis Rheum"},{"key":"3152_CR28","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhang Y, Yang S, Ye Z, Wu Q, Liu M, et al. U-shaped relation of dietary thiamine intake and new-onset hypertension. Nutrients. 2022;14(16):3251.","DOI":"10.3390\/nu14163251"},{"issue":"5","key":"3152_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11926-022-01069-3","volume":"24","author":"GK Ramos","year":"2022","unstructured":"Ramos GK, Goldfarb DS. Update on uric acid and the kidney. Curr Rheumatol Rep. 2022;24(5):132\u20138.","journal-title":"Curr Rheumatol Rep"},{"key":"3152_CR30","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int\n. 2021;100(4S):S1\u2013276.\u00a0https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"3152_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.fct.2014.04.033","volume":"69","author":"Q Shan","year":"2014","unstructured":"Shan Q, Zheng Y, Lu J, Zhang Z, Wu D, Fan S, et al. Purple sweet potato color ameliorates kidney damage via inhibiting oxidative stress mediated NLRP3 inflammasome activation in high fat diet mice. Food Chem Toxicol. 2014;69:339\u201346.","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"3152_CR32","first-page":"1608","volume":"41","author":"J Wei","year":"2018","unstructured":"Wei J, Wu H, Zhang H, Li F, Chen S, Hou B, et al. Anthocyanins inhibit high glucose-induced renal tubular cell apoptosis caused by oxidative stress in db\/db mice. Int J Mol Med. 2018;41(3):1608\u201318.","journal-title":"Int J Mol Med"},{"issue":"6","key":"3152_CR33","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71(6):851\u201365.","journal-title":"Am J Kidney Dis"},{"key":"3152_CR34","doi-asserted-by":"publisher","first-page":"9896757","DOI":"10.1155\/2019\/9896757","volume":"2019","author":"PE Chen","year":"2019","unstructured":"Chen PE, Liu CY, Chien WH, Chien CW, Tung TH. Effectiveness of cherries in reducing uric acid and gout: a systematic review. Evid Based Complement Alternat Med. 2019;2019:9896757.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"3152_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11130-021-00879-7","volume":"76","author":"AR Hillman","year":"2021","unstructured":"Hillman AR, Uhranowsky K. Acute ingestion of Montmorency tart cherry reduces serum uric acid but has no impact on high sensitivity C-reactive protein or oxidative capacity. Plant Foods Hum Nutr. 2021;76(1):83\u20139.","journal-title":"Plant Foods Hum Nutr"},{"issue":"4","key":"3152_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1515\/hsz-2013-0271","volume":"395","author":"V Iacobazzi","year":"2014","unstructured":"Iacobazzi V, Infantino V. Citrate\u2013new functions for an old metabolite. Biol Chem. 2014;395(4):387\u201399.","journal-title":"Biol Chem"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03152-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03152-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03152-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:28:35Z","timestamp":1700274515000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03152-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03152-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee from the Affiliated Hospital of Qingdao University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Nicola Dalbeth has received consulting fees, speaker fees, or grants from AstraZeneca, Dyve Biosciences, Horizon, Amgen, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, PTC Therapeutics, Protalix, Cello Health, Abbvie, and Janssen, outside the submitted work.Other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}